drugset

drugset / Trial / NCT00927823

A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

NCT00927823 ↗

Phase 1 Completed 37 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A phase 1 dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of PF-04691502 in adult cancer patients with solid tumors.

Timeline

Start: 2009-12
Primary completion: 2011-03
Completion: 2012-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-04691502	Small molecule	—	—

Indications